Citius Oncology Inc (CTOR) Stock Price, Quote & News

Company Profile

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: (908) 967-6677

Address:

11 Commerce Drive, First Floor, Cranford, United States

d_risk Dec. 26 at 6:16 AM

$CTOR - TenX Keane Acquisition - 10K - Updated Risk Factors CTOR’s 10-K sharpens risk around LYMPHIR product liability, FDA approval timing, and IP (trade secrets, trademarks, infringement), while heavily expanding post-merger equity and governance risks: dilution, volatility, Nasdaq delisting, anti-takeover and exclusive forum provisions, controlled-company status, preferred stock issuance, no dividends, and conflicts of interest with Citius Pharma. #Pharmaceuticals #EquityRisk #IntellectualProperty #FDAApproval #ProductLiability 🟢 Added 🟠 Removed https://d-risk.ai/CTOR/10-K/2025-12-23

0 · Reply

SuperGreenToday Dec. 24 at 12:42 AM

$CTOR

0 · Reply

SweStonk Dec. 23 at 11:35 PM

$CTXR $CTOR This is so weird. It is like this: FDA -> Launch -> Funding. But it should be FDA -> Funding -> Launch. I really wonder how they could say that they launched while they still dont have money for it " cough cough just as I said before". They dont have the pieces in place from A -> B(patients). Still they go out and say we launched but we miss that middle thing that cost shit ton of money, that make this launch possible but dont you worry we sure did launch. 🦍

1 · Reply

PKIT_Sensai Dec. 23 at 10:56 PM

$CTXR Please bear with the me, when I read the news. I am curious why $CTOR isn't benfiting from this news Can someone please enlighten me ? Thank you

1 · Reply

DARKP00L Dec. 23 at 10:24 PM

$CTOR 16:54 on Dec. 23 2025 CORRECTION: Citius Oncology Is The Subsidiary Of Citius Pharmaceuticals #tradeideas

0 · Reply

BALUGA825 Dec. 23 at 9:47 PM

$CTXR $CTOR News aint bad AH. We may pop tomorrow ? AH is bouncy bouncy quiete a bit now...

1 · Reply

TwongStocks Dec. 23 at 9:31 PM

$CTOR https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-year-2025-financial-results-and-provides-business-update-302648892.html

0 · Reply

TwongStocks Dec. 23 at 9:29 PM

$CTOR 10-K filed after hours https://www.sec.gov/ix?doc=/Archives/edgar/data/0001851484/000121390025125331/ea0270097-10k_citius.htm

0 · Reply

elmono Dec. 23 at 4:43 PM

$CTOR $CTXR has an 80 million valued share in CTOR, but valued at 19 million….What am I missing…valuation wise?

1 · Reply

donein12 Dec. 23 at 1:39 PM

$CTOR CTOR'S 4th qtr 9/30/25 and Y/E earnings9/30/2025 should be released before Y/E. There may be a reference/insight as to how Lymphir sales are doing in Dec--MAYBE!

0 · Reply

Market Cap	95.62M
Revenue (ttm)	0.00
Net Income (ttm)	-21.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.35

Volume	422,900
Avg Vol	539,852
Day's Range	N/A - N/A
Shares Out	83.51M
Stochastic %K	30%
Beta	2.98
Analysts	Strong Sell
Price Target	$6.00